| 5.54 0.36 (6.95%) | 09-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.59 | 1-year : | 7.7 |
| Resists | First : | 5.65 | Second : | 6.59 |
| Pivot price | 4.78  |
|||
| Supports | First : | 4.82 | Second : | 4.31 |
| MAs | MA(5) : | 5.13 |
MA(20) : | 4.79 |
| MA(100) : | 6.49  |
MA(250) : | 11.47 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 88.4 |
D(3) : | 85.5 |
| RSI | RSI(14): 59.7 |
|||
| 52-week | High : | 29.97 | Low : | 4.31 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MCRB ] has closed above the upper band by 10.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.61 - 5.63 | 5.63 - 5.64 |
| Low: | 5.12 - 5.15 | 5.15 - 5.17 |
| Close: | 5.5 - 5.54 | 5.54 - 5.57 |
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
Tue, 01 Sep 2026
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - manilatimes.net
Tue, 01 Sep 2026
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Stock Titan
Thu, 27 Aug 2026
Seres Therapeutics Inc. (MCRB) Key Financial Ratios – Valuation, Profitability & More - Value Research
Mon, 24 Aug 2026
Seres Therapeutics, Inc. SEC Filing (Aug 24, 2026) - Stock Titan
Tue, 18 Aug 2026
Seres Therapeutics (NASDAQ: MCRB) COO sells 64 shares after 181 RSUs vest - Stock Titan
Tue, 18 Aug 2026
Seres Therapeutics director Eric Shaff sells $1,196 in shares - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 8.73e+006 (%) |
| Held by Institutions | 11.4 (%) |
| Shares Short | 157 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.478e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 101.3 % |
| Return on Equity (ttm) | -39.9 % |
| Qtrly Rev. Growth | 1.88e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -317 |
| EBITDA (p.s.) | -2.19429e+008 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.33 |
| Dividend | 0 |
| Forward Dividend | 314550 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|